Procept Biorobotics (PRCT) Stock Price
Procept Biorobotics Price
Revenue has compounded at 95.5% per year over the past 6 years to 304.47 M USD. Procept Biorobotics's net margin stands at -31.4%, up from -208.8% several years earlier. Analysts set a median price target of 20.50 USD, implying 19.5% above the current price. Of 21 analysts, 10 rate the stock a buy — an overall Hold consensus.
Procept Biorobotics stock price
Procept Biorobotics business model & stock analysis
Frequently asked questions about Procept Biorobotics
The business model of PROCEPT BioRobotics Corp. is focused on developing and commercializing innovative surgical technologies. The company specializes in the design and manufacturing of the AquaBeam® System, a robotic surgical platform used for treating patients with prostate conditions. This state-of-the-art technology combines the precision of a robotic arm with the benefits of water-jet technology to provide minimally invasive procedures with increased accuracy and efficiency. PROCEPT BioRobotics Corp. aims to improve patient outcomes by delivering advanced solutions in the field of urology through their AquaBeam® System, positioning themselves as leaders in robotic-assisted surgeries for prostate treatment.
PROCEPT BioRobotics Corp is primarily active in the medical device and healthcare industries.
The main competitors of PROCEPT BioRobotics Corp in the market include companies such as Intuitive Surgical, Inc., Medtronic Plc, and Johnson & Johnson.
PROCEPT BioRobotics Corp is a renowned medical device company specializing in surgical robotics. Founded in 2002, the company has made significant strides in improving the treatment of Benign Prostatic Hyperplasia (BPH). PROCEPT BioRobotics Corp developed the revolutionary Aquablation® therapy, which utilizes advanced robotic technology to precisely and efficiently remove prostate tissue without causing significant side effects. This minimally invasive procedure has garnered recognition for its effectiveness in improving the quality of life for patients suffering from BPH. With a strong focus on innovation and patient care, PROCEPT BioRobotics Corp continues to lead the way in robotic surgical solutions for urologic conditions.
PROCEPT BioRobotics Corp has achieved several significant milestones. The company developed and gained regulatory approval for its groundbreaking Aquablation therapy, a minimally invasive treatment for benign prostatic hyperplasia (BPH). They successfully launched their flagship product, the AquaBeam® Robotic System, in the US and other international markets. PROCEPT BioRobotics Corp expanded its global presence by establishing strategic partnerships and growing its distribution network. They have consistently demonstrated strong clinical outcomes, with numerous peer-reviewed publications supporting the effectiveness and safety of Aquablation therapy. The company's milestones highlight its commitment to revolutionizing BPH treatment and improving patient outcomes worldwide.
PROCEPT BioRobotics Corp is primarily present in the United States.
PROCEPT BioRobotics Corp is committed to its core values of innovation, collaboration, and patient-centricity. With a corporate philosophy focused on developing transformative solutions for patients and healthcare providers, the company aims to revolutionize the field of surgical robotics. PROCEPT BioRobotics Corp strives to enhance patient outcomes by offering its advanced Aquablation® technology, enabling precise and personalized therapy for patients with urologic conditions. By incorporating cutting-edge robotics, the company prioritizes effective treatments and improved patient experiences. Through continuous research, development, and partnerships, PROCEPT BioRobotics Corp dedicates itself to pushing boundaries and revolutionizing the healthcare industry.
Analysts currently set an average price target of 22.13 USD for the Procept Biorobotics stock (median: 20.50 USD), implying +29.0 % versus the latest price. The consensus is based on 21 analyst ratings.
21 analysts currently rate the Procept Biorobotics stock: 10 recommend buying, 10 holding and 1 selling. For 2026, analysts expect Procept Biorobotics to generate revenue of 395.41 M USD and earnings per share of -1.65 USD.
Converted at the current exchange rate, the Procept Biorobotics share trades at 15.25 EUR (17.16 USD).
The Procept Biorobotics share (PRCT) is listed on 1 stock exchanges, including: NASDAQ (PRCT).
PROCEPT BioRobotics Corp is a global provider of innovative robotic solutions for urological surgeries. The company aims to improve patient's quality of life while increasing the efficiency of surgeons. PROCEPT BioRobotics Corp's main product is the Aquablation® System, which uses robotic technology to treat benign prostatic hyperplasia. The Aquablation® System offers numerous advantages such as faster recovery, reduced risk of complications, and immediate symptom relief. The company also offers training and education services to healthcare professionals. PROCEPT BioRobotics Corp follows a "Razor-and-Blades" business model, offering the Aquablation® System at an affordable price while generating revenue from the regular supply of consumables. The company prioritizes regulatory compliance and has implemented a global quality management system. In summary, PROCEPT BioRobotics Corp is a leading company in the field of robotic urology, providing an excellent alternative to traditional surgical treatments.
The expected revenue of Procept Biorobotics is 395.41 M USD. This figure is based on current financial data and reflects the company's business performance.
The expected profit of Procept Biorobotics is -92.78 M USD. The net profit reflects the company's profitability after deducting all expenses.
The price-to-earnings ratio (P/E) of Procept Biorobotics is currently -10.37. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Procept Biorobotics stock.
The price-to-sales ratio (P/S) of Procept Biorobotics is currently 2.43. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Procept Biorobotics stock.
The Eulerpool Quality Score for Procept Biorobotics is 2/10.
The ISIN of Procept Biorobotics is US74276L1052. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The ticker of Procept Biorobotics is PRCT. The ticker symbol is used to trade Procept Biorobotics shares on the stock exchange.
Procept Biorobotics stock
Procept Biorobotics Peer Group
Procept Biorobotics Ticker
Procept Biorobotics FIGI
All fundamentals and in-depth analysis of Procept Biorobotics
Our stock analysis for Procept Biorobotics stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Procept Biorobotics. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.